Published in:
01-12-2019 | Breast Augmentation | Hot Topics in Breast Cancer (K Hunt, Section Editor)
Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
Published in: Current Breast Cancer Reports | Issue 4/2019
Login to get accessAbstract
Purpose of Review
The US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma.
Recent Findings
Since the FDA’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigilance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal.
Summary
In the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.